Uncovering Potential: Compugen's Earnings Preview
Compugen (NASDAQ:CGEN) is set to give its latest quarterly earnings report on Monday, 2026-03-02. Here's what investors need to know before the announcement.
Analysts estimate that Compugen will report an earnings per share (EPS) of $0.10.
The announcement from Compugen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Historical Earnings Performance
The company's EPS beat by $0.02 in the last quarter, leading to a 2.99% increase in the share price on the following day.
Here's a look at Compugen's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.09 | -0.08 | -0.05 | 0.07 |
| EPS Actual | -0.07 | -0.08 | -0.08 | -0.07 |
| Price Change % | 2.99 | -1.37 | 1.44 | 7.74 |
Performance of Compugen Shares
Shares of Compugen were trading at $1.79 as of February 26. Over the last 52-week period, shares are up 1.38%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Get to Know Compugen Better
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Financial Milestones: Compugen's Journey
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Compugen's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2025, the company experienced a revenue decline of approximately -88.96%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Compugen's net margin is impressive, surpassing industry averages. With a net margin of -369.06%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Compugen's ROE excels beyond industry benchmarks, reaching -14.84%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Compugen's ROA excels beyond industry benchmarks, reaching -6.83%. This signifies efficient management of assets and strong financial health.
Debt Management: Compugen's debt-to-equity ratio is below the industry average at 0.07, reflecting a lower dependency on debt financing and a more conservative financial approach.
To track all earnings releases for Compugen visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.